AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH MALIGNANT LYMPHOMA

恶性淋巴瘤患者的自体骨髓移植

• 批准号: 3817223
• 负责人: FREDERICK APPLEBAUM
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3817223
• 关键词: Hodgkin's disease; autologous transplantation; bone marrow transplantation; busulfan; cyclophosphamide; dosage; homologous transplantation; human subject; human therapy evaluation; lymphoma; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; remission /regression

High dose chemotherapy or chemoradiotherapy followed by autologous marrow transplantation (AMT) can cure some patients of malignant lymphoma who are otherwise unlikely to be cured. In this project we propose to (1) define the curability of patients with various categories of malignant lymphoma transplanted at first relapse or second remission using a preparative regimen of CY and 12 Gy TBI; (2) compare the outcomes of syngeneic, allogeneic and autologous transplantation; (3) explore the use of AMT early in the disease course of patients with poor prognostic factors; (4) evaluate new preparative regimens in patients with lymphoma in resistant relapse and (5) measure the utility of GM-CSF posttransplant.

高剂量化疗或放化疗后自体 骨髓移植（AMT）可以治愈部分恶性肿瘤患者， 淋巴瘤，否则不太可能治愈。 在这个项目中 我们建议（1）定义各种疾病患者的可治愈性， 首次复发时移植的恶性淋巴瘤类别，或 第二次缓解采用CY和12戈伊TBI的准备方案; (2)比较同基因、同种异体和自体移植的结局 （3）探索早期应用AMT 病程中有不良预后因素的患者;（4）评估新的 难治性复发淋巴瘤患者的预处理方案 （5）检测移植后GM-CSF的作用。